Skip to content
Shorla Oncology: A Leader in Innovative Oncology Solutions
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

News

Banner

Our CEO on Biocentury’s Bio€quity Europe podcast

May 25th 2022May 18th 2022

Read More

Photo

Our CCO, Nicholas Holsman speaks at the MassBio Conference

May 25th 2022May 5th 2022

Read More

Dennis

Shorla Oncology Appoints Dennis Purcell as Chairman

April 1st 2022March 29th 2022

Read More

Shorla Oncology

Company Name Change: Shorla Pharma is now Shorla Oncology!

March 10th 2022

Read More

Photo

Shorla Oncology at Bio CEO & Investor conference, New York 2022

March 4th 2022February 14th 2022

Read More

Photo

Shorla Oncology at Euronext IPO ready programme, Dublin 2022

March 7th 2022February 14th 2022

Read More

Logo

3 Keys To A Successful Biotech Launch

February 28th 2022February 1st 2022

Read More

Logo

Shorla: making women’s and children’s cancer drugs more accessible

March 7th 2022December 22nd 2021

Read More

Banner

Shorla Oncology at ASH, Atlanta, Georgia 2021

March 7th 2022December 2nd 2021

Read More

Older posts
Newer posts
Page1 … Page12 Page13 Page14 … Page19
Logo

IRELAND HQ:
Questum Acceleration Center,
Ballingarrane Science & Technology Park,
Clonmel, Co. Tipperary,
E91 V329, Ireland

Shorla Pharma Ltd trading as Shorla Oncology®

All trademarks are the property of their respective owners.

US OFFICE:
245 Main St.,
2nd floor,
Cambridge,
MA 02142, USA

SITEMAP

PRIVACY POLICY

CALIFORNIA COMPLIANCE PROGRAM DECLARATION

Company number: 618033
©SHORLA ONCOLOGY® 2025

© 2025 Shorla Oncology: A Leader in Innovative Oncology Solutions • Built with GeneratePress
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Now approved for use in Pediatrics

  • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA).
  • Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.

Please click here for the full Prescribing information, including Boxed Warning regarding embryo-fetal toxicity, hypersensitivity reactions, and severe adverse reactions.